FibroTouch检测参数诊断非酒精性脂肪性肝炎患者效能分析*

doi:10.3969/j.issn.1672-5069.2025.01.016

Abstract

Abstract: Objective The aim of this study was to explore diagnostic performance of FibroTouch parameters in the diagnosis of non-alcoholic steatohepatitis (NASH) from individuals with non-alcoholic fatty liver diseases (NAFLD). Methods 149 patients with NAFLD were encountered in our hospital between March 2022 and March 2023, and all underwent liver biopsies. Liver stiffness measurement (LSM) and controlled attenuation parameter (CAP) were obtained by FibroTouch detection. Multivariate Logistic regression analysis was applied to find risk factors, and the area under the receiver operating characteristic curve (AUC) was used to analyze diagnostic efficacy of above parameters for NASH occurrence. Results Histo-pathological examination diagnosed NASH in 45 cases (30.2%) and simple fatty liver (SFL) in 104 cases (69.8%) in our series; body mass index (BMI), gamma-glutamyl transferase (GGT), alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and low density lipoprotein levels in patients with NASH were (29.7±1.8)kg/m², (82.6±25.7)U/L, (107.4±10.5)U/L, (74.2±16.0)U/L, (65.6±11.1)U/L and (4.2±0.9)mmol/L, all significantly higher than【 (25.6±1.5)kg/m², (50.3±19.4)U/L, (82.5±8.5)U/L, (28.9±15.2)U/L, (21.2±12.4)U/L and (3.1±0.8)mmol/L, respectively, P<0.05] in patients with SFL; CAP and LSM in NASH patients were (304.0±19.6)db/m and (13.1±2.1)kPa, both much higher than [(263.9±15.4)db/m and (8.2±1.6)kPa, respectively, P＜0.05] in SFL patients; multivariate Logistics regression analysis showed that CAP and LSM were independent risk factors for NASH occurrence (P＜0.05); the AUC was 0.901, with sensitivity of 96.8% and specificity of 82.5%, when CAP=303.7 db/m and LSM=12.9 kPa were set as cut-off-value in predicting NASH existence in individuals with NAFLD. Conclusion FibroTouch-detected LSM and CAP could help screen NASH preliminarily in individuals with NAFLD, which might guide appropriate management in clinical practice.

Key words: Non-alcoholic steatohepatitis, Non-alcoholic fatty liver diseases, Simple fatty liver, Controlled attenuation parameter, Liver stiffness measurement, Diagnosis

Shen Yue, Zhu Ning, Wang Hai. Diagnostic performance of FibroTouch parameters in the diagnosis of non-alcoholic steatohepatitis[J]. Journal of Practical Hepatology, 2025, 28(1): 60-63.

References

[1] Sheka AC, Adeyi O, Thompson J,et al. Nonalcoholic steatohepatitis: a review. JAMA,2020,323(12):1175-1183.
[2] Schwabe RF, Tabas I, Pajvani UB. Mechanisms of fibrosis development in nonalcoholic steatohepatitis. Gastroenterology, 2020,158(7):1913-1928.
[3] Grander C, Grabherr F, Tilg H. Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options. Cardiovasc Res, 2023,119(9):1787-1798.
[4] Duseja A, Singh SP, De A,et al. Indian national association for study of the liver (inasl) guidance paper on nomenclature, diagnosis and treatment of nonalcoholic fatty liver disease (NAFLD). J Clin Exp Hepatol, 2023,13(2):273-302.
[5] 陆伦根,曲颖.非酒精性脂肪性肝病的诊断与评估. 中华消化杂志,2020,40(9):584-587.
[6] Selvaraj EA, Mózes FE, Jayaswal ANA,et al. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. J Hepatol, 2021,75(4):770-785.
[7] 朱月莉,徐志鹏,郁万江,等.基于磁共振质子密度脂肪分数的青岛沿海地区非酒精性脂肪性肝病定量分析.中华肝脏病杂志,2021,29(11):1077-1082.
[8] Yu H, Liu H, Zhang J,et al. Accuracy of FibroTouch in assessing liver steatosis and fibrosis in patients with metabolic-associated fatty liver disease combined with type 2 diabetes mellitus. Ann Palliat Med, 2021,10(9):9702-9714.
[9] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪肝专家委员会.非酒精性脂肪性肝病防治指南 (2018年版).实用肝脏病杂志,2018,21(2):177-186.
[10] Kleiner DE, Brunt EM, Van Natta M, et al. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology, 2005,41(6):1313-1321.
[11] Han SK, Baik SK, Kim MY. Non-alcoholic fatty liver disease: definition and subtypes. Clin Mol Hepatol, 2023,29(suppl 1):S5-S16.
[12] Paternostro R, Trauner M. Current treatment of non-alcoholic fatty liver disease. J Intern Med, 2022,292(2):190-204.
[13] Isaacs S. Nonalcoholic fatty liver disease. Endocrinol Metab Clin North Am, 2023,52(1):149-164.
[14] 曾瑞,徐亮,马萍,等.慢性乙型肝炎合并非酒精性脂肪性肝病显著肝纤维化的影响因素分析.中华传染病杂志,2020,38(7):426-431.
[15] 李萍英,李娟,谢守珍,等.FibroTouch联合超声和CT检查诊断高原地区非酒精性脂肪性肝病临床应用研究.实用肝脏病杂志,2020,23(6):817-820.
[16] Ozercan AM, Ozkan H. Vibration-controlled transient elastography in nafld: review study. Euroasian J Hepatogastroenterol, 2022,12(Suppl 1):S41-S45.
[17] Sasso M, Beaugrand M, de Ledinghen V, et al. Controlled attenuation parameter (CAP): a novel VCTETM guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol, 2010,36(11):1825-1835.
[18] Fan L, Zhao S, Shi H, et al. Role of BMI in the relationship between dietary inflammatory index and non-alcoholic fatty liver disease: an intermediary analysis. Scand J Gastroenterol, 2023,58(10):1159-1165.
[19] Lee MS, Felipe-Dimog EB, Yang JF, et al. The efficacy of anthropometric indicators in predicting non-alcoholic fatty liver disease using fibroscan cap values among the Taiwanese population. Biomedicines, 2023,11(9):2518.
[20] 王琳,林雪松,丁楠. 非酒精性单纯性脂肪肝与非酒精性脂肪性肝炎患者血清脂质组学比较. 实用肝脏病杂志,2022,25(2):215-218.
[21] Eddowes PJ, Sasso M, Allison M, et al. Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology, 2019,156(6):1717-1730.

Diagnostic performance of FibroTouch parameters in the diagnosis of non-alcoholic steatohepatitis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Wang Changhe, Zhu Xuan, Deng Jing, et al. Preliminary diagnosis of liver fibrosis by shear wave elastography in combination with AAR, APRI and FIB-4 in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2025, 28(1): 32-35.
[2]	Hu Yu, Wang Jinghui, Wang Yao. Combination of sound palpation tissue quantification and FIB-4 index and AST/ALT ratio in evaluation of liver fibrosis in patients with hepatitis [J]. Journal of Practical Hepatology, 2025, 28(1): 36-39.
[3]	Huang Jiawei, Ji Yali, Zhou Ling, et al. SAF score and fatty liver inhibition of progression algorithm in evaluation of liver fibrosis in patients with metabolic associated fatty liver disease [J]. Journal of Practical Hepatology, 2025, 28(1): 48-51.
[4]	Ma Min, Xu Qiaoyun. Clinical implications of serum arginase-1 levels and apolipoprotein B /apolipoprotein A1 ratio in patients with non-alcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2025, 28(1): 52-55.
[5]	Yang Huiling, Zhao Wenzhe, Yang Liuqing, et al. DCE-MRI functional imaging parameters in the diagnosis of decompensated liver functions in patients with hepatitis B-related liver cirrhosis [J]. Journal of Practical Hepatology, 2025, 28(1): 92-95.
[6]	Si Tong, Zhu Jiabao, Wu Binbin. Ultrasonography and shear wave elastography in predicting high risk esophageal varices in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2025, 28(1): 100-103.
[7]	Jiang Shetian, Yan Wei, Zhao Lei, et al. Diagnostic performance of ultrasound virtual touch tissue quantification and serum liver fibrosis markers in predicting liver fibrosis in patients with hepatic schistosomiasis [J]. Journal of Practical Hepatology, 2025, 28(1): 124-127.
[8]	Fu Lin, Zhang Lingyin, Wei Qian. Application of MRI in qualitative diagnosis of focal nodular lesions of liver in patients with NAFLD [J]. Journal of Practical Hepatology, 2025, 28(1): 140-143.
[9]	Jia Jihui, Zhang Yizhi, Lin Jing, et al. Down-regulation of hepatic SREBP1 and PPAR-γ expression by naringin in mice with high-fat diet-induced NAFLD [J]. Journal of Practical Hepatology, 2024, 27(6): 816-819.
[10]	Zhou Jun, Zhang Zhongxin, Xu Haiyan. Assessment of significant liver fibrosis by visual instantaneous elastography and acoustic palpation elastography in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2024, 27(6): 832-835.
[11]	Wu Yu, Han Yuxing, Xu Manman, et al. Hospital profit and deficit of medical costs in patients with acute-on-chronic liver failure based on DRG payment reform [J]. Journal of Practical Hepatology, 2024, 27(6): 882-886.
[12]	Tang Min, Zeng Li, Yang Xinrong. FibroTouch and virtual touch tissue quantification parameters in evaluating liver fibrosis in patients with schistosomiasis-induced liver disease [J]. Journal of Practical Hepatology, 2024, 27(6): 887-890.
[13]	Chen Siyan, Guo Daoning, Zou Xiaopan, et al. Assessment of stent function by color Doppler ultrasonography in patients with liver cirrhosis and portal hypertension after transjugular intrahepatic portosystemic shunt [J]. Journal of Practical Hepatology, 2024, 27(6): 899-902.
[14]	Zeng Wang, Cai Xiaoman, Ge Shang. Enhanced MRI manifestation feature in differential diagnosis of ICC and HCC: A single center study [J]. Journal of Practical Hepatology, 2024, 27(6): 907-910.
[15]	Danba Yuzhen, Cheng Pan. Gd-EOB-DTPA-enhanced MRI scan in diagnosis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2024, 27(6): 911-914.